Key Takeaways
- The Centers for Medicare & Medicaid Services approved 2027 Medicare Advantage payment guidelines featuring a net average 2.48% rate increase — approximately $13 billion in added sector funding
- Shares of CVS Health climbed up to 5.20% in Tuesday’s session as investors responded positively to the Aetna division’s improved prospects
- The 2024 risk-adjustment methodology will remain in effect for 2027, though CMS introduced stricter protocols for diagnoses from unlinked chart reviews
- Cantor Fitzgerald maintained its Overweight stance with a $95 price objective, highlighting Medicare Advantage margin improvement as a critical catalyst
- The company’s first-quarter 2026 earnings release is scheduled for May 6, with analysts projecting $2.23 per share and $94.86 billion in revenue
CVS Health experienced a notable rally Tuesday, propelled by Medicare Advantage regulatory developments that lifted managed-care stocks across the board.
The Centers for Medicare & Medicaid Services released its final 2027 payment guidelines for Medicare Advantage and Part D programs, establishing a net average rate increase of 2.48% — representing more than $13 billion in incremental industry funding for the 2027 calendar year.
This development carries significant weight for CVS. The company maintains substantial Medicare Advantage operations through Aetna, complementing its pharmacy benefit management and retail drugstore businesses.
Investors interpreted the rate decision favorably. Shares advanced as much as 5.20% during Tuesday’s morning session.
Regulatory Adjustments Introduce New Considerations
The policy announcement contained nuanced elements. CMS determined it would maintain the 2024 risk-adjustment framework for 2027 while implementing stricter criteria that exclude unlinked chart review diagnoses from most risk-score computations.
This represents a more stringent regulatory approach that may impact insurers previously reliant on coding-intensive reimbursement methodologies. In CVS’s case, with its broad operational portfolio, market participants appeared to emphasize the funding expansion over the risk-adjustment modifications.
The company has also seen progress in its Stars rating performance. After bonus-eligible Stars scores plummeted from 85% in 2022 to just 21% in 2023 — a period that significantly pressured Medicare Advantage profitability — trends have begun reversing.
Cantor Fitzgerald, which reaffirmed its Overweight recommendation with a $95 price objective Monday, noted that while the Medicare Advantage segment still needs additional progress to achieve 3% margins, 2026 individual Medicare Advantage operations are estimated to be marginally profitable.
Prior to Tuesday’s advance, the stock was trading at $73.28, a valuation that Cantor and other firms consider discounted compared to intrinsic value.
Wall Street Maintains Positive Outlook Ahead of Upcoming Report
Analyst sentiment toward CVS remains predominantly favorable. The stock holds a consensus Buy recommendation with an average price objective of $92.79.
Recent analyst actions include Bernstein’s March upgrade to Outperform with a $94 target, Piper Sandler’s continued Overweight rating despite reducing its target to $99, and Argus Research’s sustained Buy rating at $90.
Leerink Partners maintains an Outperform rating with a $98 price target, influenced partly by the recent FTC consent decree concerning Caremark and Zinc, which the firm interpreted as eliminating a source of regulatory overhang.
On the business development front, CVS recently disclosed an asset purchase arrangement with GenieRx Holdings, designating GenieRx as the stalking horse bidder in Omnicare’s bankruptcy sale proceedings.
The company additionally named John E. Gallina, previously CFO at Elevance Health, to its board of directors and audit committee.
Looking ahead: CVS is scheduled to release first-quarter 2026 results on May 6. Consensus estimates call for earnings per share of $2.23 and revenue of $94.86 billion.
